UPLYFT program for lymphoma survivors
An Intervention for Fear of Cancer Recurrence for Lymphoma Survivors
This study is testing a new program designed to help lymphoma survivors feel better and reduce their fears about cancer coming back.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 74 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Dana-Farber Cancer Institute Academic / other |
| Locations | 1 site (Boston, Massachusetts) |
| Trial ID | NCT05080166 on ClinicalTrials.gov |
What this trial studies
This study aims to pilot the UPLYFT (Understand and Prevail: Lymphoma Fear of Recurrence Therapy) program, which provides lymphoma survivors with information and tools to enhance their quality of life and alleviate fears related to cancer recurrence. The study consists of two phases: the first involves developing the program based on feedback from clinicians and lymphoma survivors, while the second phase is a randomized pilot study testing the finalized intervention. Participants will engage in six weekly sessions and complete assessments to evaluate the program's effectiveness.
Who should consider this trial
Good fit: Ideal candidates for this study are lymphoma survivors aged 18 and older who are in complete remission and have completed their first-line treatment within the last 3 to 24 months.
Not a fit: Patients with concurrent malignancies or those under 18 years old may not benefit from this study.
Why it matters
Potential benefit: If successful, this program could significantly improve the quality of life for lymphoma survivors by reducing their fear of recurrence and associated distress.
How similar studies have performed: Other studies have shown promise in using psychological interventions to support cancer survivors, suggesting that this approach may be beneficial.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria:
Lymphoma Survivors Phase 1 and 2:
* Diagnosis of lymphoma (indolent non-Hodgkin lymphoma, aggressive non-Hodgkin lymphoma, or classic Hodgkin lymphoma)
* Age ≥ 18 years
* Interval of 3 months to 24 months from completion of first-line treatment
* In complete remission after first line of treatment
* Clinically significant FCR (score of ≥ 16 on the validated FCR Inventory-Severity Subscale \[FCRI-SS).
* Access to computer (for videoconferencing)
Lymphoma clinicians and mental health clinicians Phase 1:
* Lymphoma clinicians ≥ 1 year from oncology fellowship completion OR mental health clinicians (psychologists, social workers, psychiatrists) ≥ 1 year from completion of clinical training.
* Longitudinal clinical care for patients with lymphoma by oncologists OR provision of care for patients with cancer by mental health clinicians
Exclusion Criteria:
Lymphoma Survivors Phase 1:
* Age \< 18 years
* Concurrent other malignancy
* Patients with uncontrolled/untreated psychotic disorders or untreated bipolar and borderline personality disorder (as ascertained from medical record screen).
Lymphoma Survivors Phase 2:
* Age \< 18 years
* Concurrent other malignancy
* Patients with uncontrolled/untreated psychotic disorders or untreated bipolar and borderline personality disorders (as ascertained from medical record screen).
* Our study will exclude members of the following special populations:
* Adults unable to consent
* Individuals who are not yet adults (infants, children, teenagers)
* Pregnant women
* Prisoners
Where this trial is running
Boston, Massachusetts
- Dana-Farber Cancer Institute — Boston, Massachusetts, United States (Recruiting)
Study contacts
- Principal investigator: Oreofe O Odejide, MD, PhD — Oreofe_Odejide@dfci.harvard.edu
- Study coordinator: Oreofe O Odejide, MD, MPH
- Email: Oreofe_Odejide@dfci.harvard.edu
- Phone: (617) 632-6864
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.